PMH19 - BUDGET IMPACT ANALYSIS OF INHALED LOXAPINE FOR THE MANAGEMENT OF PSYCHOMOTOR AGITATION IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER IN ITALY

Abstract

agitation is a syndrome commonly experienced by patients suffering with bipolar disorder or schizophrenia considered as a state of cognitive and motor hyperactivity charachterized by excessive or inappropriate motor or verbal activity with marked emotional arousal. The study aimed to evaluate the clinical and economic impact of the inhaled loxapine in acutely agitated patients from the Italian National Health Service (NHS) perspective. an Excel-based budget impact model was developed in order to estimate the costs of the patients who experience agitation episode in the emergency and hospital setting. Following International Society of Pharmacoeconomics and Outcome Research (ISPOR) good practice for budget impact modelling, a systematic literature review was performed in order to identify the epidemiological and economic data for estimating the population of interest and estimate direct costs associated to the disease. Two scenarios were considered: 1) a Standard of Care scenario, with the current estimated distribution of patients over the various treatment (promazine, benzodiazepine, chlorpromazine, haloperidol, aripiprazole, valproate), versus 2) an innovative scenario, characterized by the gradual introduction of inhaled loxapine. A time horizon of 5 years was considered. the model estimated a total of 115,299 episodes of agitation from patients with schizophrenia and bipolar disorder each year (91.5% in the emergency room). These events generated 80,709 hospitalizations over 5 years, for a total cost of approximately €139.9 million. The introduction of inhaled loxapine could generate a reduction of over 1,210 hospitalisations with a cost reduction of approximately €2.1 million. The incremental expenditure for the investment on the innovative drug (+€511 thousand) was covered by the positive effects generated by the reduction of hospitalisations. Overall, inhaled loxapine generated a reduction in spending of €1.6 million five years after its introduction. hospitalisations reduction could reduce direct healthcare costs and, more important, improve the quality of life of patients.